Mycobacterial energy metabolism enzyme

Mycobacterial energy metabolism enzymes" is a collective term referring to the set of essential enzymes in Mycobacterium tuberculosis and related mycobacteria that drive the generation of ATP and maintenance of cellular energy homeostasis, primarily through oxidative phosphorylation and substrate-level phosphorylation. Key molecular components include the F₀F₁-type ATP synthase (subunits such as AtpD), NADH dehydrogenases (NDH-1 and NDH-2), cytochrome bc1 complex, cytochrome bd oxidases, succinate dehydrogenases, and cytochrome P450 enzymes. These enzymes participate in the electron transport chain, are critical for survival under aerobic and hypoxic conditions, and are required for the persistence and drug tolerance of tuberculosis bacteria. The mycobacterial ATP synthase, in particular, has been clinically validated as a drug target by the approved antitubercular drug bedaquiline, which inhibits this enzyme and depletes cellular ATP levels, leading to bactericidal activity and improved treatment of multidrug-resistant TB[1][2][3][4][6][8]. Other drugs in development (such as Q203) target the cytochrome bc1 complex. The metabolic flexibility and redundancy in some ETC components (e.g., multiple NADH dehydrogenases and terminal oxidases) present both opportunities and challenges for drug development. Assays for ATP synthase function and expression of ETC components can serve as biomarkers for drug efficacy. Notably, selectivity for mycobacterial versus host enzymes is a key safety consideration[6]. Because "Mycobacterial energy metabolism enzymes" refers to a broad class rather than a single, discrete molecular entity, this entry aggregates several enzymatic targets under a functional heading, as specifically relevant to drug discovery efforts against tuberculosis.

Other names

ATP synthase (mycobacterial)NADH dehydrogenase (mycobacterial)Cytochrome bc1 complex (mycobacterial)Succinate dehydrogenase (mycobacterial)Cytochrome P450 enzymes (mycobacterial)

Inhibition of ATP synthase activity (e.g., bedaquiline blocks mycobacterial ATP synthase) Inhibition of cytochrome bc1 complex (e.g., Q203 inhibits cytochrome bc1) Inhibition of NADH dehydrogenase (e.g., chlorpromazine and thioridazine against NDH-2) Disruption of energy production and proton motive force